Equity Profile

TGTX

TG Therapeutics, Inc.

Health CareBiotechnology$7.3B

Mar8Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EST

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.23

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with cancer and autoimmune diseases. With a market cap of $7 billion, the company is part of the health care sector, which is increasingly important as the demand for advanced medical therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

In the last quarter, TG Therapeutics reported an EPS of $0.12, which was significantly below the expected $0.23, resulting in a 16.26% increase in stock price the following day. The company has faced challenges in meeting earnings expectations consistently.

Management Promises & Guidance

Management committed to advancing their clinical pipeline.
They emphasized the importance of upcoming trial results.
They expressed confidence in their long-term growth strategy.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in profitability and progress in drug development.

Bull Case

If TG Therapeutics can exceed EPS expectations and provide positive updates on their pipeline, it could lead to increased investor confidence and a significant stock rally.

Bear Case

Conversely, if the company fails to meet earnings expectations again or provides negative updates on their clinical trials, it could lead to a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.23

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's market performance and acceptance of its products.

Pipeline Progress

N/A

Updates on the status of drug development and clinical trials can significantly impact investor sentiment and stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.23?

Exceeding this EPS target would signal a turnaround in profitability and could boost investor confidence.

What updates will be provided on the clinical pipeline?

Progress in clinical trials is critical for the company's future growth and can significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to surprise on the upside due to recent advancements in their clinical trials.

Supporting Evidence

The company's recent trial results have shown promising efficacy that may not be fully reflected in current estimates.

Options pricing indicates a lower expected move than historical averages, suggesting a potential for larger swings.

Management's commitment to pipeline advancement could yield unexpected positive news.

Key Risk

If the company reports an EPS significantly above $0.23, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether TG Therapeutics can improve its earnings performance and provide positive updates on its drug pipeline.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and suggest ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a relatively modest move, suggesting that investors are uncertain about the upcoming earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential 10.28% increase in stock price, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 4.05%, indicating continued investor concern.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Details on market reception of their latest drug offerings.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on revenue expectations and product pipeline timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Ross Stores, Inc.

Company Snapshot

TG Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for patients with cancer and autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.23

Revenue Growth

Revenue growth is crucial for assessing the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

Management Promises & Guidance

Management committed to advancing their clinical pipeline.
They emphasized the importance of upcoming trial results.
They expressed confidence in their long-term growth strategy.

Expectations

Wall Street Expectations

Bull Case

If TG Therapeutics can exceed EPS expectations and provide positive updates on their pipeline, it could lead to increased investor confidence and a significant stock rally.

Bear Case

Conversely, if the company fails to meet earnings expectations again or provides negative updates on their clinical trials, it could lead to a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.23

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's market performance and acceptance of its products.

Pipeline Progress

N/A

Updates on the status of drug development and clinical trials can significantly impact investor sentiment and stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.23?

Exceeding this EPS target would signal a turnaround in profitability and could boost investor confidence.

What updates will be provided on the clinical pipeline?

Progress in clinical trials is critical for the company's future growth and can significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for TG Therapeutics to surprise on the upside due to recent advancements in their clinical trials.

Supporting Evidence

The company's recent trial results have shown promising efficacy that may not be fully reflected in current estimates.

Options pricing indicates a lower expected move than historical averages, suggesting a potential for larger swings.

Management's commitment to pipeline advancement could yield unexpected positive news.

Key Risk

If the company reports an EPS significantly above $0.23, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on whether TG Therapeutics can improve its earnings performance and provide positive updates on its drug pipeline.

Bull Confirmed If

An EPS of $0.25 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case and suggest ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a relatively modest move, suggesting that investors are uncertain about the upcoming earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests a potential 10.28% increase in stock price, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 4.05%, indicating continued investor concern.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's commentary on cost management and operational efficiency.
3Details on market reception of their latest drug offerings.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on revenue expectations and product pipeline timelines.